Últimas noticias sobre FibroGen (NASDAQ:FGEN) Bolsa

FIBROGEN INC

FibroGen

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.

Konskie,,Poland,-,March,08,,2025:,Restoration,Hardware,Company,Logo

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADBE

BIAF

CGBS

EONR

FGEN

GNLN

HCTI

HUSA

INDO

NINE

PRZO

RNTX

RSLS

SBET

TPET

TRAW

USEG

VEON

RH sorprende con ganancias positivas en el primer trimestre y mantiene su guía para 2025, mientras sus acciones suben un 18,2 %.

Las acciones de RH se disparan un 18%; Aquí están 20 acciones que se mueven antes de la apertura del mercado

AdobeStockholm,,Sweden,-,July,26,,2021:,A,Wall,Sign,For

ZDGE

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: ADBE, MNY, RH, FGEN y ZDGE.

5 acciones en el foco este viernes: ADBE, MNY, RH, FGEN y ZDGE

FibroGen Inc

On June 12, 2025, FibroGen ("FibroGen" or the "Company") entered into a Termination, Asset Transfer and License Agreement (the "Agreement") with HiFiBiO Inc. ("HiFiBiO"). The Agreement terminates the Exclusive License and Option Agreement between the parties, dated June 16, 2021, as amended on February 14, 2024 (the "License Agreement"), and all rights and obligations of FibroGen under the License Agreement shall cease and terminate, subject to certain survival terms.
Under the Agreement, FibroGen has also licensed HiFiBiO the anti-CCR8 and anti-Gal-9 intellectual property developed by FibroGen. In the event HiFiBiO sublicenses Gal-9 (FG-3165) and/or CCR8 (FG-3175) assets, FibroGen is eligible to receive a mid single-digit to low double-digit share of HiFiBiO's license revenues and low double-digit share of HiFiBiO's commercial royalties. In the case HiFiBiO commercializes either asset, FibroGen has the potential to receive single digit royalties based upon worldwide net sales.
﻿

Contracts

FibroGen Terminates License Agreement With HiFiBiO, Transfers Anti-CCR8 And Anti-Gal-9 Assets, And Secures Potential Royalties From Future Sublicensing Or Commercialization

WIIM

FibroGen shares are trading lower after the company announced a 1-for-25 reverse stock split.

U.S. stock futures were lower this morning, with the Dow futures falling more than 500 points on Friday.
Shares of Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) fell in today's pre-market trading after the company reported second-quarter financial results and <a href="https://www.benzinga.com/quote/ADBE/earnings">raised its FY25 guidance</a>.
The company reported second-quarter revenue of $5.87 billion, beating analyst estimates of $5.79 billion, according to Benzinga Pro. The company reported second-quarter adjusted earnings of $5.06 per share, surpassing the estimated $4.96 per share.
Adobe slipped 1.8% to $406.55 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares tumbled 16.2% to $17.03 in pre-market trading after jumping over 82% on Thursday.</li>
<li>The Generation Essentials Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGE#NYSE">TGE</a>) fell 10.6% to $8.46 in pre-market trading after dipping 14% o Thursday.</li>
<li>VEON Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) shares dipped 9.9% to $42.36 in pre-market trading after jumping 5% on Thursday.</li>
<li>Arrive AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAI#NASDAQ">ARAI</a>) fell 8.8% to $8.50 in pre-market trading after gaining around 10% on Thursday. Arrive AI recently announced it obtained another patent for its AI-powered smart mailbox platform designed for autonomous and conventional package delivery.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) fell 7.3% to $3.94 in pre-market trading.</li>
<li>Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) fell 7.1% to $5.07 in pre-market trading. The company, on Thursday, announced a seven-figure NATO contract for daily monitoring and intelligence capabilities.</li>
<li>Omada Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMDA#NASDAQ">OMDA</a>) dipped 6.8% to $16.00 in pre-market trading.</li>
<li>COMPASS Pathways plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) fell 6% to $4.2500 in pre-market trading.</li>
<li>FibroGen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) fell 4.4% to $0.2949 in pre-market trading as the company reported a 1-for-25 reverse stock split.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45902941/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-q2">Top 2 Defensive Stocks That May Keep You Up At Night In Q2</a></li>
</ul>
Photo via Shutterstock

ARAI

CMPS

LAES

LIMN

OMDA

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Shares of RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) rose sharply in today's pre-market trading as the company reported upbeat earnings for the first quarter and announced that it is maintaining its current FY25 guidance despite uncertainty <a href="https://www.benzinga.com/quote/rh/earnings">surrounding tariffs and macroeconomic events.</a>
RH reported first-quarter revenue of $813.95 million, missing the consensus estimate of $818.12 million, according to Benzinga Pro. The luxury retailer reported first-quarter adjusted earnings of 13 cents per share, surpassing analyst estimates calling for a loss of nine cents per share.
RH said it sees second-quarter revenue growth of 8% to 10%, and full-year 2025 revenue growth of 10% to 13%.
RH shares jumped 18.2% to $208.98 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Houston American Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#NYSE">HUSA</a>) surged 140.3% to $16.87 in pre-market trading after gaining over 30% on Thursday.</li>
<li>U.S. Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) shares jumped 62% to $2.30 in pre-market trading after adding 3% on Thursday.</li>
<li>Indonesia Energy Corporation Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDO#NASDAQ">INDO</a>) jumped 42.4% to $5.08 in pre-market trading after gaining 10% on Thursday.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) gained 42.4% to $0.12 in pre-market trading after gaining 12% on Thursday.</li>
<li>Trio Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NYSE">TPET</a>) climbed 39.1% to $1.70 in pre-market trading after declining around 5% on Thursday.</li>
<li>Nine Energy Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) rose 23.8% to $0.7285 in pre-market trading after gaining 4% on Thursday.</li>
<li>EON Resources Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EONR#NYSE">EONR</a>) rose 22.3% to $0.6016 in pre-market trading.</li>
<li>ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) surged 19.7% to $1.40 in pre-market trading.</li>
<li>Transocean LTD (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) gained 10% to $3.53 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Sharplink Gaming Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares tumbled 64.4% to $11.60 in pre-market trading after falling 12% on Thursday.</li>
<li>Rein Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNTX#NASDAQ">RNTX</a>) dipped 18.5% to $1.60 in pre-market trading after the company announced it paused enrollment and patient dosing at its clinical trial sites in the US foe its Phase 2 RENEW trial of LTI-03.</li>
<li>Greenlane Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares fell 15% to $0.013 in pre-market trading after jumping 100% on Thursday.</li>
<li>Healthcare Triangle Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) declined 14.3% to $0.026 in pre-market trading after jumping 226% on Thursday.</li>
<li>ReShape Lifesciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) fell 12.5% to $2.72 in pre-market trading. ReShape Lifesciences jumped over 35% on Thursday after the company announced it signed an exclusive U.S. distribution agreement with Recon Supply to distribution ReShape&#8217;s portfolio across VA and DoD Healthcare Systems.</li>
<li>Traws Pharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) dipped 11.7% to $1.59 in pre-market trading.</li>
<li>bioAffinity Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) declined 10.3% to $0.27 in pre-market trading after gaining around 4% on Thursday.</li>
<li>VEON Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) declined 9.9% to $42.36 in pre-market trading after jumping 5% on Thursday.</li>
<li>FibroGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) fell 3.9% to $0.30 in pre-market trading after the company reported a 1-for-25 reverse stock split</li>
<li>Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) fell 1.8% to $406.55 in pre-market trading. Adobe reported better-than-expected second-quarter financial results and raised its FY25 guidance.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45902941/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-q2">Top 2 Defensive Stocks That May Keep You Up At Night In Q2</a> </li>
</ul>
Photo via Shutterstock

Why RH Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul class="wp-block-list">
<li>Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) reported better-than-expected second-quarter financial results and raised its FY25 guidance. The company reported second-quarter revenue of $5.87 billion, beating analyst estimates of $5.79 billion, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. The company reported second-quarter adjusted earnings of $5.06 per share, surpassing the estimated $4.96 per share. Adobe shares fell 1.5% to $407.50 in the after-hours trading session.</li>
<li>Wall Street expects MoneyHero Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNY#NASDAQ">MNY</a>) to report earnings results for the first quarter before the opening bell today. MoneyHero shares gained 5% to $0.8505 in after-hours trading.</li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) reported upbeat earnings for the first quarter and announced that it is maintaining its current FY25 guidance despite uncertainty surrounding tariffs and macroeconomic events. RH said it sees second-quarter revenue growth of 8% to 10%, and full-year 2025 revenue growth of 10% to 13%. RH shares jumped 20.3% to $212.75 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul class="wp-block-list">
<li>FibroGen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) reported a 1-for-25 reverse stock split. FibroGen shares dipped 4.1% to $0.2959 in the after-hours trading session.</li>
<li>Zedge, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZDGE#NYSE">ZDGE</a>) posted stronger-than-expected earnings for the third quarter on Thursday. The company reported quarterly earnings of 6 cents per share, which beat the analyst consensus estimate of 2 cents per share. Zedge shares climbed 13.9% to $3.19 in after-hours trading.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45902941/top-2-defensive-stocks-that-may-keep-you-up-at-night-in-q2">Top 2 Defensive Stocks That May Keep You Up At Night In Q2</a> </li>
</ul>
Photo courtesy: Mats Wiklund / Shutterstock.

Adobe, RH And 3 Stocks To Watch Heading Into Friday

Stock Split

FibroGen To Implement 1-For-25 Reverse Stock Split, Will Begin Trading On A Split-Adjusted Basis On June 17, 2025

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock moved upwards by 47.4% to $0.72 during Monday's after-market session. The market value of their outstanding shares is at $5.8 million. </li>
<li>MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) shares moved upwards by 15.95% to $47.75. The company's market cap stands at $3.0 billion. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares rose 8.91% to $0.32. The company's market cap stands at $32.3 million. </li>
<li>Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) stock rose 8.19% to $6.6. The company's market cap stands at $109.0 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) shares moved upwards by 7.92% to $32.0. The market value of their outstanding shares is at $209.9 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares rose 7.27% to $0.51. The company's market cap stands at $10.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock fell 22.7% to $1.7 during Monday's after-market session. The market value of their outstanding shares is at $24.4 million. </li>
<li>Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) shares fell 17.82% to $1.43. The company's market cap stands at $52.7 million. </li>
<li>Clene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) stock declined by 16.29% to $4.1. The market value of their outstanding shares is at $36.8 million. </li>
<li>Rapport Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPP#NASDAQ">RAPP</a>) shares decreased by 7.65% to $8.7. The company's market cap stands at $317.5 million. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) stock decreased by 7.1% to $0.62. The market value of their outstanding shares is at $74.2 million. </li>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) stock fell 7.03% to $4.1. The market value of their outstanding shares is at $151.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDMD

CLNN

MLTX

MODV

OWLT

RAPP

TLPH

TOVX

UNCY

12 Health Care Stocks Moving In Monday's After-Market Session

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) with a Buy and maintains $10 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on FibroGen, Maintains $10 Price Target

FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.02 by 150 percent. This is a 115.15 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $2.74 million which beat the analyst consensus estimate of $2.00 million by 36.95 percent. This is a 95.10 percent decrease over sales of $55.90 million the same period last year.

Earnings

Earnings Beats

FibroGen Q1 EPS $0.05 Beats $0.02 Estimate, Sales $2.74M Beat $2.00M Estimate

ACHC

ACHR

ACNT

AGEN

AIRJ

ALLT

ALTI

AMBC

AMPY

APEI

AQST

ARCT

ARWR

ASRT

ASYS

AUPH

BATRA

BATRK

Mobile Infrastructure Corporation Common Stock

BEEP

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLDE

BLNK

CATX

CEPU

CHGG

CHRS

CLLS

CLPR

CMCL

CMPO

CNNE

CNTY

CPSS

CTMX

CTRI

CWCO

DOLE

EDIT

EXOD

FOXA

FRPH

FTEK

FTRE

GAIA

GETY

GPRO

GRDN

HBIO

HFFG

HNRG

IHRT

IMNN

INDI

ISPR

KBDC

KPTI

KSPI

LAND

LEGH

LINC

LSEA

LTBR

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MFIC

MLNK

MLYS

MNDY

MODG

MRVI

MVIS

MVST

NMRA

NOTE

NPWR

NRGV

NRXS

Earnings Scheduled For May 12, 2025

FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.
Analysts estimate that FibroGen will report an earnings per share (EPS) of $-0.10. 
The market awaits FibroGen's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.12, leading to a 21.8% drop in the share price on the subsequent day.
Here's a look at FibroGen's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.20</td>
<td>-0.30</td>
<td>-0.26</td>
<td>-0.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.08</td>
<td>-0.17</td>
<td>-0.16</td>
<td>-0.33</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-22.0%</td>
<td>-14.000000000000002%</td>
<td>5.0%</td>
<td>18.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746821173_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of FibroGen were trading at $0.3194 as of May 08. Over the last 52-week period, shares are down 74.54%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/FGEN/earnings">To track all earnings releases for FibroGen visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of FibroGen's Earnings

FibroGen Announces Publication Of Results From Phase 1 Monotherapy Study Of FG-3246 In Patients With Metastatic Castration-Resistant Prostate Cancer In Journal of Clinical Oncology; Says Initiation Of Phase 2 Monotherapy Dose Optimization Study Of FG-3246 In mCRPC Expected By Mid-2025

<h3>Gainers</h3>
<ul>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares rose 14.6% to $1.81 during Wednesday's after-market session. The company's market cap stands at $10.3 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock moved upwards by 11.0% to $2.22. The market value of their outstanding shares is at $2.4 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock rose 8.43% to $0.45. The market value of their outstanding shares is at $2.2 million. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) shares moved upwards by 6.36% to $0.62. The market value of their outstanding shares is at $52.7 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares rose 6.11% to $0.22. The market value of their outstanding shares is at $6.6 million. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares moved upwards by 5.7% to $0.38. The company's market cap stands at $38.1 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) shares fell 20.4% to $2.26 during Wednesday's after-market session. The market value of their outstanding shares is at $533.8 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock declined by 7.54% to $1.35. The market value of their outstanding shares is at $39.9 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 6.63% to $0.27. The market value of their outstanding shares is at $1.6 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) stock declined by 6.32% to $1.78. The company's market cap stands at $15.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares declined by 6.03% to $3.05. The market value of their outstanding shares is at $2.0 million. </li>
<li>LENZ Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LENZ#NASDAQ">LENZ</a>) stock declined by 5.96% to $24.0. The market value of their outstanding shares is at $660.0 million. As per the news, the Q4 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKBA

APDN

BCLI

DYAI

IPSC

LENZ

SCNX

SHPH

VERO

Longevity Health Holdings, Inc. - Common Stock

XAGE

YCBD

12 Health Care Stocks Moving In Wednesday's After-Market Session

FibroGen shares are trading lower. The company reported Q4 financial results.

FibroGen Q4 EPS From Continuing Operations $(0.08), Revenue From Continuing Operations $3.100M

<h3>Companies Reporting Before The Bell</h3>
• Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) is expected to report quarterly earnings at $1.68 per share on revenue of $597.66 million. 
• LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $23.55 million. 
• NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is likely to report earnings for its fourth quarter. 
• CBAK Energy Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBAT#NASDAQ">CBAT</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $50.11 million. 
• Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $20.21 million. 
• NextPlat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPL#NASDAQ">NXPL</a>) is projected to report earnings for its fourth quarter. 
• Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) is projected to report quarterly earnings at $2.07 per share on revenue of $1.81 billion. 
• Inspired Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSE#NASDAQ">INSE</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $81.72 million. 
• Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) is projected to report earnings for its fourth quarter. 
• Coda Octopus Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODA#NASDAQ">CODA</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $5.74 million. 
• Niu Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIU#NASDAQ">NIU</a>) is likely to report earnings for its fourth quarter. 
• Townsquare Media (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSQ#NYSE">TSQ</a>) is expected to report quarterly earnings at $0.58 per share on revenue of $116.41 million. 
<h3>Companies Reporting After The Bell</h3>
• DiaMedica Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMAC#NASDAQ">DMAC</a>) is likely to report earnings for its fourth quarter. 
• Belite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLTE#NASDAQ">BLTE</a>) is expected to report earnings for its fourth quarter. 
• High Tide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HITI#NASDAQ">HITI</a>) is estimated to report earnings for its first quarter. 
• Eastman Kodak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) is expected to report earnings for its fourth quarter. 
• Health In Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIT#NASDAQ">HIT</a>) is estimated to report earnings for its first quarter. 
• Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) is likely to report earnings for its fourth quarter. 
• Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $24.03 million. 
• Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) is expected to report quarterly loss at $0.11 per share on revenue of $42.51 million. 
• Natural Gas Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>) is projected to report quarterly earnings at $0.25 per share on revenue of $40.84 million. 
• Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) is projected to report quarterly loss at $0.14 per share on revenue of $3.77 million. 
• FinVolution Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FINV#NYSE">FINV</a>) is likely to report earnings for its fourth quarter. 
• FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) is expected to report quarterly loss at $0.20 per share on revenue of $24.91 million. 
• Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) is likely to report earnings for its fourth quarter. 
• Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) is likely to report quarterly loss at $1.25 per share on revenue of $21.61 million. 
• B. Riley Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) is estimated to report earnings for its fourth quarter. 
• Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $33.60 million. 
• RF Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RFIL#NASDAQ">RFIL</a>) is expected to report earnings for its first quarter. 
• Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $59.09 million. 
• Hallador Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) is likely to report quarterly loss at $0.05 per share on revenue of $102.46 million. 
• Altus Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $46.55 million. 
• Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $244.87 million. 
• Lithium Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAR#NYSE">LAR</a>) is expected to report quarterly loss at $0.04 per share on revenue of $48.40 million. 
• Quanterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTRX#NASDAQ">QTRX</a>) is projected to report quarterly loss at $0.22 per share on revenue of $35.55 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMPS

BLTE

CBAT

CODA

DMAC

FINV

HITI

HROW

HYPR

INSE

KODK

LNZA

LPRO

NRXP

NXPL

QFIN

QTRX

RBOT

RFIL

RILY

SAIC

SGMO

SNDA

Earnings Scheduled For March 17, 2025

FibroGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) stock is trading higher on Thursday. The company&nbsp;announced the sale of its China subsidiary to AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43842973/fibrogen-announces-the-sale-of-fibrogen-china-to-astrazeneca-for-approximately-160-million" rel="noreferrer noopener">approximately $160 million</a>.
&#8220;Today, we announced the sale of FibroGen China to AstraZeneca, our long-time strategic partner for roxadustat in China, bolstering our company on several fronts. It strengthens our financial position, meaningfully extending our cash runway into 2027, and enables us to continue progressing the clinical development program for FG-3246, our first-in-class, CD46 targeting antibody-drug conjugate, and FG-3180, our companion PET imaging agent, in mCRPC,&#8221; said Thane Wettig, Chief Executive Officer of FibroGen.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43065029/astrazeneca-aims-to-restore-trust-with-new-leadership-in-china-amid-scandal-and-sales-decline" rel="noreferrer noopener">AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline</a>
FibroGen will receive an enterprise value of $85 million plus FibroGen net cash in China at closing, estimated to be approximately $75 million, totaling roughly $160 million. The transaction is expected to close by mid-2025.
AstraZeneca will obtain all rights to roxadustat for anemia in chronic kidney disease in China. A regulatory decision for chemotherapy-induced anemia is pending.
FibroGen maintains its rights to roxadustat in the U.S. and in all markets not licensed to Astellas. The company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome.
The company is planning for an FDA meeting in the second quarter of 2025 to determine the potential next steps for the development program for roxadustat in the U.S.
In relation to the illegal drug importation allegations, in January 2025, AstraZeneca received a Notice of Transfer to the Prosecutor and an Appraisal Opinion from the Shenzhen City Customs Office regarding suspected unpaid importation taxes amounting to $0.9 million, referred to in the Appraisal Opinion relate to cancer drugs, <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43527514/astrazeneca-q4-earnings-revenue-and-eps-beat-on-higher-cancer-and-respiratory-drug-sales-faces-4-5-million-potential-fine-in-china" rel="noreferrer noopener">Imfinzi and Imjudo</a>.
A fine of one and five times unpaid importation taxes may also be levied if AstraZeneca is found liable (amounting to around $0.9 million to $4.5 million). Reuters notes the update reassures analysts and investors that the business impact would be minor.
AstraZeneca&#8217;s China sales fell 1% on a reported basis to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41907137/astrazeneca-lifts-2024-forecast-on-better-than-expected-q3-performance-says-it-takes-china-invest" rel="noreferrer noopener">$1.36 billion (-3% at CER)</a>.
Price Action: FGEN stock is up 21.6% at $0.68 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43852190/southern-company-q4-utility-growth-boosts-revenue-but-rising-costs-weigh-on-profit" target="_blank" rel="noreferrer noopener">Southern Company Q4: Utility Growth Boosts Revenue, But Rising Costs Weigh on Profit</a></li>
</ul>
Image by Robert Way via Shutterstock

Biotech

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

Comments

FibroGen

Noticias

Últimas noticias sobre FibroGen (NASDAQ:FGEN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL